J
James A. Bonner
Researcher at University of Alabama at Birmingham
Publications - 252
Citations - 17463
James A. Bonner is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Radiation therapy & Cetuximab. The author has an hindex of 56, co-authored 237 publications receiving 16175 citations. Previous affiliations of James A. Bonner include University of Alabama & University of Michigan.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
James A. Bonner,Paul M. Harari,Jordi Giralt,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,José Baselga,Sharon A. Spencer,Junming Zhu,Hagop Youssoufian,Eric K. Rowinsky,K. Kian Ang +12 more
TL;DR: Overall survival was significantly improved in those who experienced an acneiform rash of at least grade 2 severity compared with patients with no rash or grade 1 rash, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients.
Journal ArticleDOI
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
K. Kian Ang,Qiang Zhang,David I. Rosenthal,Phuc Felix Nguyen-Tan,Eric J. Sherman,Randal S. Weber,James M. Galvin,James A. Bonner,Jonathan Harris,Adel K. El-Naggar,Maura L. Gillison,Richard C.K. Jordan,Andre Konski,Wade L. Thorstad,Andy Trotti,Jonathan J. Beitler,Adam S. Garden,William J. Spanos,Sue S. Yom,Rita Axelrod +19 more
TL;DR: Adding cetuximab to radiation-cisplatin did not improve outcome and hence should not be prescribed routinely, and the PFS and OS were higher in patients with p16-positive OPC, but outcomes did not differ by EGFR expression.
Journal ArticleDOI
Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
Francisco Robert,Mark P. Ezekiel,Sharon A. Spencer,Ruby F. Meredith,James A. Bonner,M. B. Khazaeli,Mansoor N. Saleh,Delicia Carey,Albert F. LoBuglio,Richard H. Wheeler,Michael R. Cooper,Harlan W. Waksal +11 more
TL;DR: The most commonly reported adverse events were fever, asthenia, transaminase elevation, nausea, and skin toxicities (grade 1 to 2 in most patients).
Journal ArticleDOI
Patterns of Surgical Care of Lung Cancer Patients
Alex G. Little,Valerie W. Rusch,James A. Bonner,Laurie E. Gaspar,Mark R. Green,W. Richard Webb,Andrew K. Stewart +6 more
TL;DR: Patients being operated for NSCLC are elderly with significant comorbid conditions and Mediastinoscopy is infrequently performed and lymph nodes are biopsied in less than 50% of them, and positive surgical margins are too frequent.